JP2004528307A5 - - Google Patents

Download PDF

Info

Publication number
JP2004528307A5
JP2004528307A5 JP2002573009A JP2002573009A JP2004528307A5 JP 2004528307 A5 JP2004528307 A5 JP 2004528307A5 JP 2002573009 A JP2002573009 A JP 2002573009A JP 2002573009 A JP2002573009 A JP 2002573009A JP 2004528307 A5 JP2004528307 A5 JP 2004528307A5
Authority
JP
Japan
Prior art keywords
keto
ketoalkanoic acid
group
mediated
ketoalkanoic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002573009A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004528307A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/008283 external-priority patent/WO2002074301A1/en
Publication of JP2004528307A publication Critical patent/JP2004528307A/ja
Publication of JP2004528307A5 publication Critical patent/JP2004528307A5/ja
Pending legal-status Critical Current

Links

JP2002573009A 2001-03-15 2002-03-15 サイトカインにより媒介される炎症性状態の治療のためのピルベートおよび/またはその誘導体の使用方法 Pending JP2004528307A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27627901P 2001-03-15 2001-03-15
PCT/US2002/008283 WO2002074301A1 (en) 2001-03-15 2002-03-15 Method of using pyruvate and/or its derivatives for the treatment of cytokine-mediated inflammatory conditions

Publications (2)

Publication Number Publication Date
JP2004528307A JP2004528307A (ja) 2004-09-16
JP2004528307A5 true JP2004528307A5 (enExample) 2005-12-22

Family

ID=23055992

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002573009A Pending JP2004528307A (ja) 2001-03-15 2002-03-15 サイトカインにより媒介される炎症性状態の治療のためのピルベートおよび/またはその誘導体の使用方法

Country Status (6)

Country Link
US (2) US6943190B2 (enExample)
EP (1) EP1379230A4 (enExample)
JP (1) JP2004528307A (enExample)
AU (1) AU2002255805B2 (enExample)
CA (1) CA2440480A1 (enExample)
WO (1) WO2002074301A1 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303321B1 (en) 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
AU2002255805B2 (en) * 2001-03-15 2005-03-24 North Shore Long Island Jewish Research Institute Method of using pyruvate and/or its derivatives for the treatment of cytokine-mediated inflammatory conditions
EP1377339A4 (en) * 2001-04-04 2006-05-31 Critical Therapeutics Inc PROCEDURE FOR PREVENTING AKUTER NIERENINSUFFIZIENZ
US20030013846A1 (en) 2001-05-03 2003-01-16 Bing Wang Pyruvate derivatives
US7304034B2 (en) 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
US8076373B2 (en) * 2001-09-11 2011-12-13 North Cell Pharmacetical Method for treating mammalian diseases and injuries caused by the over-expression of peroxynitrite
US7122578B2 (en) * 2001-09-11 2006-10-17 Alain Martin Method and composition for treating mammalian diseases and injuries which cause pain, erythema, swelling, crusting, ischemia scarring and excess white blood cell infiltration
CN1671742A (zh) * 2002-07-03 2005-09-21 塔博尔山圣拉弗尔基金中心 Hmgb1在治疗组织损伤和/或促进组织修复中的用途
EP1581223B2 (en) * 2002-12-06 2016-05-25 The Feinstein Institute for Medical Research Inhibition of inflamation using alpha 7 receptor-binding cholinergic agonists
US7696169B2 (en) 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
WO2005004857A1 (en) * 2003-06-09 2005-01-20 University Of Pittsburgh Of The Commonwealth System Of Higher Education Method for treating acute pancreatitis
DE602004014140D1 (de) * 2003-06-13 2008-07-10 Univ Pittsburgh Verfahren zur behandlung von alkoholischer hepatitis
ES2222093A1 (es) 2003-07-01 2005-01-16 Advanced In Vitro Cell Technologies, S.L. Metodo para el almacenamiento y/o transporte de cultivos celulares in vitro.
AU2004272607B2 (en) 2003-09-11 2008-11-06 Cornerstone Therapeutics Inc. Monoclonal antibodies against HMGB1
JP2007526022A (ja) * 2003-10-24 2007-09-13 メドトロニック・インコーポレーテッド 炎症誘発性媒介物質の産生を減弱することによって神経性障害を処置する技法
EP1814576A2 (en) * 2004-07-20 2007-08-08 Critical Therapeutics, Inc. Combination therapies of hmgb and complement inhibitors against inflammation
US20060253100A1 (en) 2004-10-22 2006-11-09 Medtronic, Inc. Systems and Methods to Treat Pain Locally
WO2006108681A2 (en) 2005-04-15 2006-10-19 Biomac Privatinstitut Für Medizinische Und Zahnmedizinische Forschung, Entwicklung Und Diagnostik Gmbh Substances and pharmaceutical compositions for the inhibition of glyoxalases and their use against bacteria
EP1909834A2 (en) * 2005-07-18 2008-04-16 Critical Therapeutics, Inc. Use of hmgb1 antagonists for the treatment of inflammatory skin conditions
WO2007120544A2 (en) * 2006-04-12 2007-10-25 Alexander Rayna L Compositions comprising pyruvate alkyl esters and uses thereof
US7754247B2 (en) * 2007-05-29 2010-07-13 University Of South Carolina Resuscitation fluid
US8114907B2 (en) * 2007-08-08 2012-02-14 Cellular Sciences Inc Method for treating a pulmonary disease state in mammals by up regulating indigenous in vivo levels of inflammatory agents in mammalian cells
US8211943B2 (en) * 2007-08-08 2012-07-03 Alain Martin Method for treating a pulmonary disease state in mammals by up regulating indigenous in vivo levels of inflammatory agents in mammalian cells
US8815946B2 (en) * 2008-01-25 2014-08-26 University of Pittsburgh—of the Commonwealth System of Higher Education Inhibition of proliferation and fibrotic response of activated corneal stromal cells
JP5630750B2 (ja) * 2008-03-18 2014-11-26 国立大学法人 岡山大学 興奮性化学伝達調節剤およびそのスクリーニング法
USRE48948E1 (en) 2008-04-18 2022-03-01 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
US8445717B2 (en) 2008-11-20 2013-05-21 Chd Bioscience, Inc. α-Keto alkylperacids and methods for producing and using the same
MX2011005207A (es) 2008-11-20 2011-07-20 Chata Biosystems Inc Alfa-ceto peracidos y metodos para producir y utilizar los mismos.
CA2750140C (en) 2008-12-30 2015-10-06 Hill's Pet Nutrition, Inc. Use of lipoic acid for treating or preventing degenerative joint conditions, osteoarthritis, cartilage damage, and related disorders in companion animals
US20100239632A1 (en) 2009-03-23 2010-09-23 Warsaw Orthopedic, Inc. Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue
JP6154136B2 (ja) 2009-12-29 2017-06-28 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド コンパニオン動物のためのピルベートを含む組成物、およびその使用法
US11284621B2 (en) 2010-04-15 2022-03-29 Armis Biopharma, Inc. Compositions comprising peroxyacid and methods for producing and using the same
US9044527B2 (en) 2011-02-17 2015-06-02 Chd Bioscience, Inc. Wound care products with peracid compositions
KR20140008394A (ko) * 2011-02-17 2014-01-21 시에이치디 바이오사이언스 인코포레이티드 퍼옥시 α-케토카르복실산을 포함하는 조성물 및 이를 생산하고 사용하기 위한 방법
US9913880B2 (en) * 2011-02-18 2018-03-13 Stemdr Inc. Method of treating sepsis or septic shock
WO2012170740A2 (en) * 2011-06-07 2012-12-13 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
WO2012170742A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Treatment and prevention of cancer with hmgb1 antagonists
CA2888056A1 (en) 2012-10-18 2014-04-24 Chd Bioscience, Inc. Compositions comprising alpha-peroxyacid and non alpha-peroxyacid, and methods for producing and using the same
US9578879B1 (en) 2014-02-07 2017-02-28 Gojo Industries, Inc. Compositions and methods having improved efficacy against spores and other organisms
DE102017131059A1 (de) * 2017-12-22 2019-06-27 Christiane Kappert Physiologisch verträgliche Lösung mit einem Gehalt an Pyruvat und Glycin, eine Pyruvat und Glycin enthaltende Zusammensetzung und Verfahren zu deren Herstellung
EP3797766A1 (en) * 2019-09-24 2021-03-31 Evonik Operations GmbH Compositions for use in reducing inflammation

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2307075A (en) * 1940-08-02 1943-01-05 Carbide And Carbon Chemicais C Vinyl resin composition
US4105782A (en) * 1975-03-07 1978-08-08 Yu Ruey J Treatment of acne and dandruff
US4197316A (en) * 1975-07-23 1980-04-08 Scott Eugene J Van Treatment of dry skin
JPS539847A (en) * 1976-07-15 1978-01-28 Akishima Kagaku Kogyo Stabilized halogenncontained resin composition
US4234599A (en) * 1978-10-04 1980-11-18 Scott Eugene J Van Treatment of skin keratoses with α-hydroxy acids and related compounds
US4246261A (en) * 1979-08-09 1981-01-20 Scott Eugene J Van Additives enhancing topical corticosteroid action
DE3133132A1 (de) * 1981-08-21 1983-03-03 Schweiger Hubert Terpene in synergistisch wirkenden kombinationen mit (alpha)-ketomono- und/oder (alpha)-ketodicarbonsaeuren und/oder deren mono- bzw. mono- und/oder diester und verwendung dieser pflanzlichen wirkstoffkombinationen als bioaktive mittel in arznei-, kosmetischen und dermatologischen mitteln
DE3581407D1 (de) * 1985-09-06 1991-02-21 Nestle Sa Bewahrung lebender gewebe.
US6051609A (en) * 1997-09-09 2000-04-18 Tristrata Technology, Inc. Additives enhancing the effect of therapeutic agents
WO1992004826A1 (en) * 1990-09-21 1992-04-02 Regents Of The University Of Minnesota Pyruvate solutions to counteract acute renal failure
US5210098A (en) * 1990-09-21 1993-05-11 Regents Of The University Of Minnesota Use of pyruvate to treat acute renal failure
US5648380A (en) * 1991-03-01 1997-07-15 Warner-Lambert Company Anti-inflammatory wound healing compositions and methods for preparing and using same
AU2694592A (en) * 1991-09-30 1993-05-03 Walser, Mackenzie Methods for treatment of free-radical-mediated tissue injury
DE4415581C2 (de) * 1994-05-04 1995-12-07 Voith Gmbh J M Papier-Streichvorrichtung
US5536751A (en) * 1994-05-09 1996-07-16 The United States Of America As Represented By The Secretary Of The Army Pharmaceutical alpha-keto carboxylic acid compositions method of making and use thereof
US5480909A (en) * 1994-08-08 1996-01-02 University Of Pittsburgh Medical Center Method for inhibiting generation of free-radicals
US5908611A (en) * 1995-05-05 1999-06-01 The Scripps Research Institute Treatment of viscous mucous-associated diseases
AU719332B2 (en) * 1995-09-19 2000-05-04 Cellular Sciences, Inc. Method and composition for treating mammalian diseases caused by inflammatory response
US5798388A (en) * 1996-09-06 1998-08-25 Cellular Sciences, Inc. Method and composition for treating mammalian diseases caused by inflammatory response
US6086789A (en) * 1996-03-18 2000-07-11 Case Western Reserve University Medical uses of pyruvates
US5756469A (en) * 1996-07-26 1998-05-26 Beale; Paxton K. Composition of pyruvate and anti-cortisol compounds and method for increasing protein concentration in a mammal
US6417231B1 (en) * 1996-12-23 2002-07-09 Frank L. Greenway Method and composition for delivering therapeutically effective amounts of pyruvate to a mammal
MXPA01011521A (es) 1999-05-14 2003-08-20 Cellular Sciences Inc Metodo y composicion para tratar las enfermedades nasales y de los senos paranasales causadas por una respuesta inflamatoria en los mamiferos.
US6846842B2 (en) * 1999-10-07 2005-01-25 Beth Israel Deconess Medical Center, Inc. Pyruvate ester composition and method of use for resuscitation after events of ischemia and reperfusion
CN1377266A (zh) * 1999-10-07 2002-10-30 安瑟斯生命科学公司 丙酮酸酯组合物和其在缺血和灌流后复苏中的应用方法
AU2002255805B2 (en) * 2001-03-15 2005-03-24 North Shore Long Island Jewish Research Institute Method of using pyruvate and/or its derivatives for the treatment of cytokine-mediated inflammatory conditions

Similar Documents

Publication Publication Date Title
JP2004528307A5 (enExample)
JP2004501189A5 (enExample)
CN1088992C (zh) 治疗眼炎的含3-苯甲酰基苯乙酸衍生物的局部给药组合物
JP3778516B2 (ja) 新規なアリールプロピオン酸誘導体、その製造方法及び鎮痛薬としてのその用途
RU2003135482A (ru) Геропротектор на основе гидрированных пиридо(4,3-b) индолов (варианты), фармакологическое средство на его основе и способ его применения
JP2011510080A5 (enExample)
JP2012521429A5 (enExample)
JP2004516314A5 (enExample)
RU2006105804A (ru) Нитрооксипроизводные лозартана, валсартана, кандесартана, телмисартана, эпросартана и олмесартана в качестве блокаторов рецепторов ангиотензина ii для лечения сердечно-сосудистых заболеваний
JP2004512318A (ja) C−ニトロソ化合物とその使用
RU2003103286A (ru) Ингибиторы медьсодержащих аминооксидаз
RU2008109914A (ru) Применение производных тиенопиридона в качестве активаторов амфк и фармацевтические композиции, которые их содержат
RU99110944A (ru) Тиенопиримидины с ингибирующим действием по отношению к фосфодиэстеразе v (pde v)
JP2009530398A5 (enExample)
JP2011507896A5 (enExample)
RU2004134604A (ru) Тетрагидропиранилциклопентилтерагидропиридопиридиновые модуляторы активности рецептора хемокина
RU2005128501A (ru) Соединение для лечения метаболических расстройств
RU2000116899A (ru) Тиенопиримидины
CA2522738A1 (en) Compounds for the treatment of metabolic disorders
CA2521621A1 (en) Compounds for the treatment of metabolic disorders
EP1494659B1 (en) Pharmaceutical composition comprising an alpha-ketoalkanoic acid ester or -amide and lactic acid or a lactic acid salt
EP2941252A2 (en) Use of fatty acid niacin conjugates for treating diseases
JP2007501800A5 (enExample)
RU2000129659A (ru) Конденсированные тиенопиримидины с ингибирующим фосфодиэстеразу v действием
RU96123227A (ru) Амидные производные и их терапевтическое использование